Back to top

Image: Bigstock

If You Invested $1000 in Intuitive Surgical, Inc. 10 Years Ago, This Is How Much You'd Have Now

Read MoreHide Full Article

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.

The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.

What if you'd invested in Intuitive Surgical, Inc. (ISRG - Free Report) ten years ago? It may not have been easy to hold on to ISRG for all that time, but if you did, how much would your investment be worth today?

Intuitive Surgical, Inc.'s Business In-Depth

With that in mind, let's take a look at Intuitive Surgical, Inc.'s main business drivers.

Headquartered Sunnyvale, CA, Intuitive Surgical Inc designs, manufactures and markets the da Vinci surgical system, Ion endoluminal system and related instruments and accessories. The da Vinci surgical system is an advanced robot-assisted surgical system. The surgical system comprises a surgeon’s console, patient-side cart, 3-D vision system, da Vinci Skills Simulator and Firefly Fluorescence Imaging.

Intuitive Surgical’s robot-based da Vinci surgical system enables minimally-invasive surgery that reduces the trauma associated with open surgery. The da Vinci System is powered by robotic technology which has provided the company with a solid exposure to Mechatronics, Robotocs and Artificial Intelligence for healthcare. The system provides 3-D High Definition vision, which helps surgeons gain superior visual clarity of target tissue and anatomy.Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform that utilizes instruments and accessories for minimally invasive biopsies in the lung. The system can be used beyond surgery into diagnostic, endoluminal procedures as well.

It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures.  Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies.

The company operates through three segments: Instruments and Accessories, Systems and Services.

2025 Results at a Glance

Intuitive Surgical’s 2025 revenues totaled $10.1 billion, up 20.5% from 2024. The company’s Instruments & Accessories sales were $6.02 billion (59.8% of net revenues), Systems revenues were $2.47 billion (24.6%) and Services revenues grossed $1.57 billion (15.6%).

Bottom Line

Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Intuitive Surgical, Inc. a decade ago, you're probably feeling pretty good about your investment today.

A $1000 investment made in August 2016 would be worth $5,191.77, or a gain of 419.18%, as of August 12, 2026, according to our calculations. This return excludes dividends but includes price appreciation.

The S&P 500 rose 253.57% and the price of gold increased 211.89% over the same time frame in comparison.

Analysts are anticipating more upside for ISRG.

Intuitive Surgicalbeat second-quarter estimates for earnings and sales.The company's broad robotic platform, rising installed base and recurring revenue model support durable growth. Da Vinci 5, SP and Ion adoption should widen procedure reach, while digital tools deepen customer engagement. Procedure growth remains healthy, and the balance sheet supports product development and manufacturing investment. However, U.S. procedure growth has moderated in deferrable categories, bariatric volumes remain weak, and China faces lower tender activity, local competition and pricing constraints. Tariffs, product mix and the planned extended-use instrument program may also limit margins and instruments revenue per procedure. Hospital budget cycles can still disrupt placements outside the United States.

Over the past four weeks, shares have rallied 5.73%, and there have been 11 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.

Published in